In-vitro and in-vivo activity of a new quinolone AM-1155 against mycoplasma pneumoniae

Kazuo Ishida, Mitsuo Kaku, Kenji Irifune, Ryusuke Mizukane, Hiromu Takemura, Ryouji Yoshida, Hironori Tanaka, Toshiaki Usui, Kazunori Tomono, Naofumi Suyama, Hironobu Koga, Shigeru Kohno, Kohei Hara

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

We investigated the in-vitro and in-vivo activity of a new quinolone AM-1155 against Mycoplasma pneumoniae, and compared it with ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline. AM-1155 was the most potent agent in vitro of the quinolones tested. Its pre-treatment minimal inhibitory concentrations for 90% of the 41 strains (MIC 90 ) was 0.06 mg/L.In contrast, pre-treatment MIC 90 values for ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin, and minocycline were 1, 1, 2, 0.5, 0.0156, and 0.5 mg/L, respectively. Post-treatments MIC 90 s, which may reflect mycoplasmacidal potency, of AM-1155, ofloxacin, ciprofloxacin, lomefloxacin, tosufloxacin, erythromycin and minocycline were 0.125, 1, 2, 4, 0.5, 0.125 and 4 mg/L, respectively.In-vitro activities of antimicrobial agents were assessed in an experimental pulmonary infection model in Syrian golden hamsters. AM-1155 was the most effective agent among five antimicrobial agents (AM-1155, ofloxacin, tosufloxacin, erythromycin, minocycline) tested in terms of reduction in viable M. pneumoniae cells and in reducing macroscopic lung lesions. These results suggest that AM-1155 will be a useful antimicrobial agent for the treatment of M. pneumoniae infections.

Original languageEnglish
Pages (from-to)875-883
Number of pages9
JournalJournal of Antimicrobial Chemotherapy
Volume34
Issue number6
DOIs
Publication statusPublished - 1994 Dec 1
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'In-vitro and in-vivo activity of a new quinolone AM-1155 against mycoplasma pneumoniae'. Together they form a unique fingerprint.

  • Cite this

    Ishida, K., Kaku, M., Irifune, K., Mizukane, R., Takemura, H., Yoshida, R., Tanaka, H., Usui, T., Tomono, K., Suyama, N., Koga, H., Kohno, S., & Hara, K. (1994). In-vitro and in-vivo activity of a new quinolone AM-1155 against mycoplasma pneumoniae. Journal of Antimicrobial Chemotherapy, 34(6), 875-883. https://doi.org/10.1093/jac/34.6.875